Key facts
- J-Pharma (TKS: 520A)’s last known valuation is $99.4M (Mar 2026).
- It has raised $83.1M; the latest was IPO ($20.8M) in Mar 2026.
- Notable investors include Mitsubishi UFJ Capital, F-Prime Capital, Eight Roads, Japan External Trade Organization, JIC Venture Growth Investments — 30 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for J-Pharma (TKS: 520A)
- ·The full record, as it builds
Funding rounds
No funding rounds for J-Pharma (TKS: 520A) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About J-Pharma (TKS: 520A)
J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. It is focused on a single segment of the drug discovery business, focusing on R&D and clinical development. The company's two compounds in clinical development are Nanbran Latte (JPH203) and JPH034.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2005
- Employees
- 16
- Website
- j-pharma.com/
- Ownership
- Publicly Held
J-Pharma (TKS: 520A) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in J-Pharma (TKS: 520A) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on J-Pharma (TKS: 520A) in its N-PORT filings yet. We sweep new filings monthly.